Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHB4 | P54760 | 2/20 | 0.69 |
| ▸ | KDR | P35968 | 4/20 | 0.62 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.62 |
| ▸ | IGF1R | P08069 | 2/20 | 0.61 |
| ▸ | EGFR | P00533 | 2/20 | 0.55 |
| ▸ | JAK2 | O60674 | 1/20 | 0.55 |
| ▸ | CDK2 | P24941 | 1/20 | 0.55 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.55 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.55 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.55 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.55 |
| ▸ | PTK2 | Q05397 | 8/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.52 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.52 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.52 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.52 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.52 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.52 |
| ▸ | AURKA | O14965 | 2/20 | 0.51 |
| ▸ | TEK | Q02763 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13325996 | 0.84 | PTK2 (0.62) | EPHB4KDRAURKBIGF1REGFR | |
| SCHEMBL4941396 | 0.84 | EPHB4 (0.64) | EPHB4KDRAURKBIGF1REGFR | |
| SCHEMBL6479290 | 0.82 | EPHB4 (0.50) | EPHB4KDRAURKBIGF1REGFR | |
| SCHEMBL21067672 | 0.82 | EPHB4 (1.00) | EPHB4KDRAURKBIGF1REGFR | |
| SCHEMBL1927928 | 0.82 | IGF1R (0.61) | EPHB4KDRAURKBIGF1RJAK2 | |
| SCHEMBL6480192 | 0.82 | IGF1R (0.65) | EPHB4KDRAURKBIGF1RJAK2 | |
| SCHEMBL6482909 | 0.80 | SRC (0.52) | EPHB4KDRAURKBIGF1REGFR | |
| SCHEMBL15398857 | 0.79 | PTK2 (0.60) | EPHB4KDRAURKBIGF1REGFR | |
| SCHEMBL14214721 | 0.78 | IGF1R (0.68) | EPHB4KDRAURKBIGF1REGFR | |
| SCHEMBL13955883 | 0.78 | IGF1R (0.59) | EPHB4KDRAURKBIGF1REGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9522904-B2 | Method for producing triazinyl-substituted oxindoles | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-12-20 | — | — | US | disclosed |
| EP-2655361-B1 | PROCESS FOR THE PREPARATION OF TRIAZINYL SUBSTITUTED OXINDOLES | BAYER IP GMBH (DE) | 2016-02-24 | — | — | EP | disclosed |
| US-20150126737-A1 | METHOD FOR PRODUCING TRIAZINYL-SUBSTITUTED OXINDOLES | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2015-05-07 | — | — | US | disclosed |
| US-8962828-B2 | Method for producing triazinyl-substituted oxindoles | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-02-24 | — | — | US | disclosed |
| EP-2824099-A1 | NOVEL TRIAZINE DERIVATIVE | Carna Biosciences Inc. (JP) | 2015-01-14 | — | — | EP | disclosed |
| US-20150011751-A1 | NOVEL TRIAZINE DERIVATIVE | CARNA BIOSCIENCES, INC. (JP) | 2015-01-08 | — | — | US | disclosed |
| EP-1218360-B1 | TRIAZINE KINASE INHIBITORS | AMGEN INC (US) | 2008-05-28 | — | — | EP | disclosed |
| EP-1218360-B1 | TRIAZINE KINASE INHIBITORS | AMGEN INC (US) | 2008-05-28 | — | — | EP | disclosed |
| US-7074789-B2 | Kinase inhibitors | AMGEN INC. (US) | 2006-07-11 | — | — | US | disclosed |
| US-6881737-B2 | Substituted triazinyl acrylamide derivatives and methods of use | AMGEN INC. (US) | 2005-04-19 | — | — | US | disclosed |
| US-6864255-B2 | Substituted triazinyl amide derivatives and methods of use | AMGEN INC. (US) | 2005-03-08 | — | — | US | disclosed |
| US-20040116388-A1 | triazine compoound inhibitors of enzymes that catalyze phosphoryl transfer and/or that bind ATP/GTP nucleotides | AMGEN INC. | 2004-06-17 | — | — | US | disclosed |
| EP-1390354-A1 | TRIAZINYL ACRYLAMIDE DERIVATIVES AS KINASE INHIBITORS | Amgen Inc. (US) | 2004-02-25 | — | — | EP | disclosed |
| EP-1385833-A1 | TRIAZINYL AMIDE DERIVATIVES AS ANGIOGENESIS INHIBITORS | Amgen Inc. (US) | 2004-02-04 | — | — | EP | disclosed |
| US-20030139416-A1 | Substituted triazinyl acrylamide derivatives and methods of use | AMGEN INC. | 2003-07-24 | — | — | US | disclosed |
| US-20030087908-A1 | Substituted triazinyl amide derivatives and methods of use | AMGEN INC. | 2003-05-08 | — | — | US | disclosed |
| WO-2002083653-A1 | TRIAZINYL ACRYLAMIDE DERIVATIVES AS KINASE INHIBITORS | AMGEN INC. (US) | 2002-10-24 | — | — | WO | disclosed |
| WO-2002083654-A1 | TRIAZINYL AMIDE DERIVATIVES AS ANGIOGENESIS INHIBITORS | AMGEN INC. (US) | 2002-10-24 | — | — | WO | disclosed |
| EP-1218360-A1 | TRIAZINE KINASE INHIBITORS | Amgen Inc., (US) | 2002-07-03 | — | — | EP | disclosed |
| WO-2001025220-A1 | TRIAZINE KINASE INHIBITORS | AMGEN INC. (US) | 2001-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139416-A1 | Substituted triazinyl acrylamide derivatives and methods of use | PKD1, PKD2, GLS | EPHB4 3547/4885KDR 1851/4885AURKB 1605/4885 |
| US-20150011751-A1 | NOVEL TRIAZINE DERIVATIVE | HDAC5, IL5, AGTR2 | EPHB4 4421/4885KDR 1535/4885AURKB 3244/4885 |
| US-20150126737-A1 | METHOD FOR PRODUCING TRIAZINYL-SUBSTITUTED OXINDOLES | TPI1, OXSR1, HPD | EPHB4 4777/4885KDR 4007/4885AURKB 4449/4885 |
| US-20030087908-A1 | Substituted triazinyl amide derivatives and methods of use | FLT4, FLT1, VEGFA | EPHB4 2420/4885KDR 4/4885AURKB 2115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.